BioSpace News Archive

The combined company, Palisade Bio, Inc., is expected to commence trading on the Nasdaq Capital Market under the ticker symbol “PALI” on April 28, 2021

Arcline Investment Management, a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, announced the acquisition of Polypeptide Therapeutic Solutions, S.L. from Columbus Venture Partners.

The response to the COVID-19 pandemic has included measures to slow the spread of the virus taken by governments and health care authorities globally, including the postponement of elective medical procedures and social contact restrictions.

Penumbra, Inc. announced that its management team is scheduled to present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced an upcoming presentation at The American Society for Aesthetic Plastic Surgery Aesthetic Meeting 2021, being held at The Miami Beach Convention Center in Miami Beach, FL from April 29 – May 3, 2021.

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, announced that it intends to offer and sell, subject to market and other conditions, $125 million of shares of its common stock in an underwritten public offering.

Accuray Incorporated reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021.

Perrigo Company plc, a leading provider of Quality, Affordable Self-Care Products, announced that it will release its fiscal first quarter financial results on Tuesday, May 11, 2021.

Mark Barberio appointed Chairman of the Board of Directors effective at 2021 Annual General Meeting

Varian, a Siemens Healthineers company, has signed an agreement with Australia’s Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden.